Quantum Biopharma (QNTM) Expected to Release Earnings on Thursday

Quantum Biopharma (NASDAQ:QNTM) is expected to issue its results before the market opens on Thursday, August 6th. Analysts expect Quantum Biopharma to post earnings of ($0.4116) per share for the quarter.

Quantum Biopharma Stock Performance

QNTM opened at $3.05 on Tuesday. The company has a market capitalization of $19.52 million, a P/E ratio of -0.37 and a beta of 0.43. The company has a 50-day moving average of $3.88 and a 200-day moving average of $4.25. Quantum Biopharma has a 1-year low of $2.07 and a 1-year high of $31.91.

Institutional Trading of Quantum Biopharma

A hedge fund recently bought a new stake in Quantum Biopharma stock. Virtu Financial LLC purchased a new position in Quantum Biopharma Ltd. (NASDAQ:QNTM) during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm purchased 10,406 shares of the company’s stock, valued at approximately $76,000. Virtu Financial LLC owned about 0.27% of Quantum Biopharma as of its most recent filing with the Securities and Exchange Commission. 1.24% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of equities analysts recently commented on QNTM shares. Wall Street Zen upgraded Quantum Biopharma from a “strong sell” rating to a “sell” rating in a research note on Saturday. Weiss Ratings cut Quantum Biopharma from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Thursday, May 28th. One research analyst has rated the stock with a Sell rating, According to data from MarketBeat, Quantum Biopharma currently has an average rating of “Sell”.

About Quantum Biopharma

Quantum Biopharma Ltd. is a biotechnology pharmaceutical research and development company, which focuses on the cultivation, process, and sale of medical cannabis. It operates through the Biotechnology and Strategic Investments segments. The Biotechnology segment is involved in the research and development of the company’s three drug candidates consisting of FSD-PEA, Lucid-PSYCH, and Lucid-MS. The Strategic Investments segment is focused on generating returns and cashflow through the issuance of loans secured by residential or commercial property.